Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Key Inclusion Criteria:

- Age 18 years and above.

- Diagnosis of AD as defined by the Hanifin and Rajka 1980 criteria for AD.

- History of AD for ≥1 year.

- AD involvement of 5-50% treatable body surface area at screening and at baseline
(excluding scalp).

- Disease severity graded as mild to severe according to vIGA-AD (i.e. vIGA-AD ≥2) at
screening and baseline.

Key Exclusion Criteria:

- AD lesion(s) on scalp at screening and/or baseline.

- Active dermatologic conditions that may confound the diagnosis of AD or would
interfere with assessment of treatment, such as scabies, cutaneous lymphoma, rosacea,
urticaria, or psoriasis.

- Known active allergic or irritant contact dermatitis that is likely to interfere with
the assessment of severity of AD.

- Use of tanning beds or phototherapy within 4 weeks prior to baseline.

- Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4
weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to
baseline.

- Treatment with topical corticosteroids, topical calcineurin inhibitors, topical
phosphodiesterase-4 inhibitors, or oral antibiotics within 2 weeks prior to baseline.

- Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e. the
subjects must not start antihistamine treatment or change the current dosage regime
within 2 weeks prior to baseline.

- Receipt of live attenuated vaccines within 4 weeks prior to baseline.

- Treatment with any marketed or investigational biologic agents within 6 months or 5
half-lives prior to baseline, or until cell counts return to normal, whichever is
longer.

- History of any active skin infection within 1 week prior to baseline.

- Clinically significant infection (systemic infection or serious skin infection
requiring parenteral treatment) within 4 weeks prior to baseline.